Abstract
Carriers of the hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) gene variant (rs72613567:TA) have a reduced risk of NASH and cirrhosis but not steatosis. We determined its effect on liver histology, lipidome, and transcriptome using ultra performance liquid chromatography-mass spectrometry and RNA-seq. In carriers and noncarriers of the gene variant, we also measured pathways of hepatic fatty acids (de novo lipogenesis [DNL] and adipose tissue lipolysis [ATL] using 2H2O and 2H-glycerol) and insulin sensitivity using 3H-glucose and euglycemic-hyperinsulinemic clamp) and plasma cytokines. Carriers and noncarriers had similar age, sex and BMI. Fibrosis was significantly less frequent while phospholipids, but not other lipids, were enriched in the liver in carriers compared with noncarriers. Expression of 274 genes was altered in carriers compared with noncarriers, consisting predominantly of downregulated inflammation-related gene sets. Plasma IL-6 concentrations were lower, but DNL, ATL and hepatic insulin sensitivity were similar between the groups. In conclusion, carriers of the HSD17B13 variant have decreased fibrosis and expression of inflammation-related genes but increased phospholipids in the liver. These changes are not secondary to steatosis, DNL, ATL, or hepatic insulin sensitivity. The increase in phospholipids and decrease in fibrosis are opposite to features of choline-deficient models of liver disease and suggest HSD17B13 as an attractive therapeutic target.
Introduction
Nonalcoholic fatty liver disease (NAFLD) is a global epidemic, yet its progression is highly variable. While many individuals exhibit simple steatosis (fatty liver) without further complications, others progress to nonalcoholic steatohepatitis (NASH), characterized by inflammation and fibrosis, which can lead to cirrhosis or hepatocellular carcinoma. Recently, a protein-truncating variant of the HSD17B13 gene (rs72613567:TA) was identified as protective against this progression. However, the mechanism behind this protection remained unclear. This study aims to elucidate the metabolic and molecular pathways through which the HSD17B13 variant exerts its protective effects by analyzing the liver lipidome, transcriptome, and systemic metabolism in human subjects.
Methods
The study involved 485 human subjects, categorized into carriers of the protective variant (TTA/TATA) and non-carriers (TT). Liver biopsies from a cohort of 202 subjects undergoing bariatric surgery were analyzed using the SAF (Steatosis, Activity, and Fibrosis) scoring system, ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) for lipidomics, and RNA-seq for transcriptomics. Additionally, a metabolic cohort of 283 subjects underwent stable isotope tracer studies ($^2H_2O$ and $^2H$-glycerol) to measure de novo lipogenesis and adipose tissue lipolysis, alongside euglycemic-hyperinsulinemic clamps with tritiated glucose to assess hepatic insulin sensitivity.
Results
Histological and Metabolic Findings
The primary finding was a significant reduction in liver fibrosis among carriers of the HSD17B13 variant. Specifically, fibrosis (stage ≥ 1) was present in only 25.0% of carriers compared to 42.4% of non-carriers. Notably, the protective effect was specific to fibrosis and did not extend to the initial accumulation of liver fat.
Despite the reduction in scarring, the prevalence of steatosis was similar between the two groups, confirming that the variant's protection occurs downstream of fat accumulation.
Furthermore, there were no significant differences in systemic metabolic markers, including BMI, de novo lipogenesis, or hepatic insulin sensitivity, suggesting the mechanism is localized within the liver.
Lipidomic and Transcriptomic Insights
Lipidomic analysis revealed a significant enrichment of phospholipids, particularly phosphatidylcholines and phosphatidylethanolamines, in the livers of carriers. This profile is the inverse of what is observed in choline-deficient models of liver disease, which are known to induce inflammation and fibrosis. Transcriptomic data supported these findings, showing a downregulation of 254 inflammation-related gene sets in carriers, including genes like ALOX5 and TGFB2. The decrease in PLD4, a phospholipid-degrading enzyme, likely contributes to the observed phospholipid accumulation.
Discussion
This study demonstrates that the HSD17B13 variant protects against liver fibrosis by altering the liver's lipid environment and suppressing inflammatory pathways. By increasing the levels of essential phospholipids, the variant appears to stabilize cell membranes and lipid droplets, making the liver more resilient to the damage typically associated with NAFLD. This "anti-choline-deficiency" effect decouples fat accumulation from subsequent inflammatory damage. Given these findings, HSD17B13 represents a highly promising therapeutic target for preventing the progression of NAFLD to more severe stages of liver disease. Future research should focus on validating the specific enzymatic substrates of HSD17B13 and exploring pharmacological inhibition as a treatment strategy.
Summary updated